Vol 18, No 4 (2013)
Original research articles
Published online: 2013-07-01

open access

Page views 156
Article views/downloads 186
Get Citation

Connect on Social Media

Connect on Social Media

Empirical estimation of beam-on time for prostate cancer patients treated on Tomotherapy

Małgorzata Skórska1, Tomasz Piotrowski12
DOI: 10.1016/j.rpor.2012.12.005
Rep Pract Oncol Radiother 2013;18(4):201-208.

Abstract

Background and aim

This study proposed a method to estimate the beam-on time for prostate cancer patients treated on Tomotherapy when FW (field width), PF (pitch factor), modulation factor (MF) and treatment length (TL) were given.

Material and methods

The study was divided into two parts: building and verifying the model. To build a model, 160 treatment plans were created for 10 patients. The plans differed in combination of FW, PF and MF. For all plans a graph of beam-on time as a function of TL was created and a linear trend function was fitted. Equation for each trend line was determined and used in a correlation model. Finally, 62 plans verified the treatment time computation model – the real execution time was compared with our estimation and irradiation time calculated based on the equation provided by the manufacturer.

Results

A linear trend function was drawn and the coefficient of determination R2 and the Pearson correlation coefficient r were calculated for each of the 8 trend lines corresponding to the adequate treatment plan. An equation to correct the model was determined to estimate more accurately the beam-on time for different MFs. From 62 verification treatment plans, only 5 disagreed by more than 60[[ce:hsp sp="0.25"/]]s with the real time from the HT software. Whereas, for the equation provided by the manufacturer the discrepancy was observed in 16 cases.

Conclusions

Our study showed that the model can well predict the treatment time for a given TL, MF, FW and it can be used in clinical practice.

Article available in PDF format

View PDF Download PDF file



Reports of Practical Oncology and Radiotherapy